Search
Rilonacept
go.drugbank.com/drugs/DB06372ApprovedInvestigationalRilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) … and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.
Midazolam
go.drugbank.com/drugs/DB00683ApprovedIllicitInvestigational[L45098] In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. … [L45098] In May 2019, the nasal spray of midazolam was approved for the acute treatment of distinctive intermittent, stereotypic seizure episodes in patients 12 years of age and older.
Products: N/a, Midazolam in Sodium ChlorideRituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalOn November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808]. … Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.
Bendroflumethiazide
go.drugbank.com/drugs/DB00436ApprovedInvestigationalIt has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)
Anisotropine methylbromide
go.drugbank.com/drugs/DB00517Approvedaction on the bile ducts and gallbladder. … Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents.
Apomorphine
go.drugbank.com/drugs/DB00714ApprovedInvestigationalIt was first synthesized in 1845 and first used in Parkinson's disease in 1884. … [A203597,A203618] Apomorphine was granted FDA approval on 20 April 2004.[L13919]
Categories: Drugs Used in Erectile DysfunctionProducts: APO-GO PEN 10 MG/ML, Apo-go Pen 10 mg/ml - InjektionslösungSirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigational[A242417] Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. … [A1320] Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants.
Products: LIKMUN-EBifidobacterium longum infantis
go.drugbank.com/drugs/DB14222ApprovedInvestigationalWithdrawnMixtures: BİOBER-ZN ORAL SÜSPANSİYON İÇEREN FLAKON, 5 ADETSotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigationalfound to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. … [L41369] Sotrovimab was granted marketing authorization in the European Union in December 2021 under the brand name Xevudy.[L39625,L39620]